CMB Cambium Bio Limited
Healthcare · Biotechnology
· website
$0.55
52wk 0.34 – 0.60
Overall
58.8
Value
52.0
Growth
100.0
Health
41.1
Quality
0.0
Momentum
95.5
Dividend
—
Price
About Cambium Bio Limited
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Price analytics
Returns
| 1 day | 4.8% |
| 1 week | -0.9% |
| 1 month | 21.1% |
| 3 months | 25.3% |
| 6 months | 58.0% |
| 1 year | 10.1% |
| 3 years | -9.2% |
Risk
| Volatility (1y ann.) | 64.9% |
| Beta vs ASX 200 | -0.34 |
| Sharpe (1y) | 0.40 |
| VaR 95% (1-day) | -6.7% |
| Max drawdown (1y) | -42.5% |
| Off 1-year high | -9.2% |
Technicals
| RSI(14) | 69 |
| vs 50DMA | 22.5% |
| vs 200DMA | 19.3% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
52.0
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
24
Price / Sales
0
Growth
100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
41.1
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
9
Debt / Equity
100
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
95.5
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
100
Position in 52-week range
79
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$16.04M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.17
Dividend yield
—
Payout ratio
0.0%
Beta
-0.15
EV / EBITDA
-4.00
Price / Book
6.26
ROE
-194.4%
Operating margin
-342.5%
Net margin
0.0%
Total cash
$1.12M
Total debt
$149,804
Current ratio
0.95
Debt / Equity
0.06
Free cash flow
$-1.99M
Avg volume
3,946
Latest annual results
(FY ending 30 Jun 2026)
- Revenue—
- Gross profit—
- Operating income-$4.81M
- Net income-$4.10M
- Diluted EPS-0.17
- Free cash flow-$2.81M
- Net debt-$966.36K